Brief: Matinas Biopharma Receives Orphan Drug Designation From U.S. FDA For Mat2203
07/10/2019 13:31
Oct 7 (Reuters) - Matinas BioPharma Holdings Inc MTNB.A :
* MATINAS BIOPHARMA RECEIVES ORPHAN DRUG DESIGNATION FROM
U.S. FDA
FOR MAT2203 FOR THE TREATMENT OF CRYPTOCOCCOSIS
Source text for Eikon: ID:
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors